Latest Information
June 8th, 2016.
Nivolumab was associated with improved quality of life compared with everolimus in patients with previously treated renal cell carcinoma.  
April 25th, 2016
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. 
March 24th, 2016
In a phase II trial of patients with metastatic clear cell renal cell carcinoma, everolimus was associated with better progression-free survival than apitolisib.
Print this page Tell A Friend Add to Favorites

Dr. Kevin Zbuk

B.Sc. (Alberta), MD (Alberta), FRCPC


Assistant Professor, McMaster University
Department of Oncology - Division of Medical Oncology




Office:

Juravinski Cancer Centre
3rd Floor
699 Concession Street
Hamilton Ontario, L8V 5C2

Contact Information:
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E:kevin.zbuk@jcc.hhsc.ca

Support Staff:
Karen Chadwick (Administrative Assistant)
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E: Karen.Chadwick@jcc.hhsc.ca

Areas of Interest

Dr. Zbuk's areas of interest include cancer genetics and the molecular classification of gastrointestinal polyposis syndromes. Dr. Zbuk's oncology practice focuses on gastrointestinal malignancies.

Selected Publications

Zbuk K and Eng C “Cancer Phenomics: RET and PTEN as illustrative models”. Nature Reviews Cancer. 2007 Jan;7(1):35-45.

Ni Y*, Zbuk K*, Sadler T, et. al. « Germline mutations and variants in the succinate dehydrogenase genes in Cowden andCowden-like syndromes” American Journal of Human Genetics 2008 (in press)

Plon, S.E., Pirics, M.L., Agrawal, S., Zbuk, K., Nuchtern, J., Hicks, J., Hegde, M., Lip-Hon Chin, E., Eng, C., and H. Russell (2008). Multiple Tumors in a Child with Germline Mutations in TP53 and PTEN. New England J of Medicine, in press.

* joint first authors